Descripción de negocio
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Consejo de gestión & Consejo de supervisión
| CEO |
| Tim Van Hauwermeiren |
| Consejo de gestión |
| Karen Massey, Karl Gubitz, Peter Ulrichts, Malini Moorthy, Luc Truyen, Arjen Lemmen, Andria Wilk, Marc Schorpion, Beth DelGiacco, Filip Borgions |
| Consejo de supervisión |
| Peter Verhaeghe, Don deBethizy, Pamela M. Klein, A.A. Rosenberg, James M. Daly, Camilla Sylvest, Ana Cespedes, Steve Krognes, Tim Van Hauwermeiren |
Datos de la empresa
| Nombre: |
argenx SE |
| Dirección: |
Laarderhoogtweg 25,NL-1101 EB Amsterdam |
| Teléfono: |
- |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.argenx.com/ |
| Industria: |
Biotechnology |
| Sector: |
Biotechnology |
| Subsector: |
Biotechnology |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
07/10/2014 |
Relación con inversores
| Nombre: |
Beth DelGiacco |
| IR teléfono: |
+31 (0) 763 030 488 |
| IR-fax: |
- |
| IR e-mail: |
bdelgiacco@argenx.com
|
